Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25397533,trough concentration,Mean week 1 RPV trough concentration was 0.083 mg/L and comparable to phase III trial data (p=0.747).,"The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25397533/),[mg] / [l],0.083,35740,DB08864,Rilpivirine
,26918544,AUC0-24,"Median (range) AUC0-24 were 1969 (867-4987, n = 15), 1669 (556-4312, n = 28), and 2387 (188-6736, n = 28) ng·h/mL in the second trimester, the third trimester, and postpartum, respectively (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[h·ng] / [ml],1969,37770,DB08864,Rilpivirine
,26918544,AUC0-24,"Median (range) AUC0-24 were 1969 (867-4987, n = 15), 1669 (556-4312, n = 28), and 2387 (188-6736, n = 28) ng·h/mL in the second trimester, the third trimester, and postpartum, respectively (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[h·ng] / [ml],1669,37771,DB08864,Rilpivirine
,26918544,AUC0-24,"Median (range) AUC0-24 were 1969 (867-4987, n = 15), 1669 (556-4312, n = 28), and 2387 (188-6736, n = 28) ng·h/mL in the second trimester, the third trimester, and postpartum, respectively (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[h·ng] / [ml],2387,37772,DB08864,Rilpivirine
,26918544,C24,"Median (range) C24 were 63 (37-225, n = 17), 56 (<10-181, n = 30), and 81 (<10-299, n = 28) ng/mL (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],63,37773,DB08864,Rilpivirine
,26918544,C24,"Median (range) C24 were 63 (37-225, n = 17), 56 (<10-181, n = 30), and 81 (<10-299, n = 28) ng/mL (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],56,37774,DB08864,Rilpivirine
,26918544,C24,"Median (range) C24 were 63 (37-225, n = 17), 56 (<10-181, n = 30), and 81 (<10-299, n = 28) ng/mL (P < 0.05 for either trimester vs postpartum).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],81,37775,DB08864,Rilpivirine
,26918544,cord blood/maternal concentration ratio,"Median (range) cord blood/maternal concentration ratio was 0.55 (0.3-0.8, n = 21).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),,0.55,37776,DB08864,Rilpivirine
,26918544,Cmin,"Cmin were significantly lower at 15 visits with detectable HIV-1 RNA compared with 61 visits with undetectable HIV-1 RNA, 29 (<10-93) vs 63 (15-200) ng/mL (P = 0.0001).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],29,37777,DB08864,Rilpivirine
,26918544,Cmin,"Cmin were significantly lower at 15 visits with detectable HIV-1 RNA compared with 61 visits with undetectable HIV-1 RNA, 29 (<10-93) vs 63 (15-200) ng/mL (P = 0.0001).",Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],63,37778,DB08864,Rilpivirine
below,26918544,EC90 concentration,Cmin was below the protein binding-adjusted EC90 concentration (12.2 ng/mL) at 4 visits in 3 of 31 women (10%).,Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26918544/),[ng] / [ml],12.2,37779,DB08864,Rilpivirine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,101,38982,DB08864,Rilpivirine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,87,38983,DB08864,Rilpivirine
,28219799,recovery,"The mean recovery of RPV, DTG and EVG were 101%, 87% and 112.3% respectively.","UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28219799/),%,112.3,38984,DB08864,Rilpivirine
,24521854,protein binding,Mean and individual plasma concentrations of nevirapine and rilpivirine were compared with the proposed plasma target concentration for nevirapine (3000 ng/mL) and the protein binding-adjusted EC90 for rilpivirine (12.1 ng/mL).,Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),[ng] / [ml],12.1,39726,DB08864,Rilpivirine
,24521854,EC90,Mean and individual plasma concentrations of nevirapine and rilpivirine were compared with the proposed plasma target concentration for nevirapine (3000 ng/mL) and the protein binding-adjusted EC90 for rilpivirine (12.1 ng/mL).,Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),[ng] / [ml],12.1,39727,DB08864,Rilpivirine
,24521854,EC50,"Mean rilpivirine CSF and SP concentrations were calculated and individual values compared with the EC50 and EC90 for wild-type virus (0.27 and 0.66 ng/mL, respectively).",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),[ng] / [ml],0.27,39728,DB08864,Rilpivirine
,24521854,EC90,"Mean rilpivirine CSF and SP concentrations were calculated and individual values compared with the EC50 and EC90 for wild-type virus (0.27 and 0.66 ng/mL, respectively).",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),[ng] / [ml],0.66,39729,DB08864,Rilpivirine
,24521854,trough concentration,"By day 3, the mean plasma rilpivirine trough concentration was 29.7 ng/mL (95% CI: 23.8-37).",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),[ng] / [ml],29.7,39730,DB08864,Rilpivirine
,24521854,concentration,"The mean rilpivirine concentration in CSF was 0.8 ng/mL (95% CI: 0.7-1.0), representing a CSF : plasma ratio of 1.4%, with concentrations above the EC90 in 85% (11/13) of patients.",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),ng,0.8,39731,DB08864,Rilpivirine
,24521854,CSF : plasma ratio,"The mean rilpivirine concentration in CSF was 0.8 ng/mL (95% CI: 0.7-1.0), representing a CSF : plasma ratio of 1.4%, with concentrations above the EC90 in 85% (11/13) of patients.",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),,1,39732,DB08864,Rilpivirine
,24521854,SP : plasma ratio,"In SP, the mean rilpivirine concentration was 4.9 ng/mL (95% CI: 3.3-7.2), representing an SP : plasma ratio of 9.5%, with all concentrations above the EC90.",Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24521854/),,9,39733,DB08864,Rilpivirine
,28845699,Cmax,Enhanced oral bioavailability was observed in fasted Sprawley rats where Cmax and AUC0-∞ increases significantly (Cmax of NS∼ 586 ± 5.91 ng/mL; plain RLP ∼310 ± 5. 74 ng/mL).,Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845699/),[ng] / [ml],586,47285,DB08864,Rilpivirine
,28845699,Cmax,Enhanced oral bioavailability was observed in fasted Sprawley rats where Cmax and AUC0-∞ increases significantly (Cmax of NS∼ 586 ± 5.91 ng/mL; plain RLP ∼310 ± 5. 74 ng/mL).,Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28845699/),[ng] / [ml],∼310,47286,DB08864,Rilpivirine
,24161160,AUC24h,"Norethindrone pharmacokinetics were unaffected by rilpivirine (AUC24h: 0.89, 0.84 - 0.94; Cmin: 0.99, 0.90 - 1.08; Cmax: 0.94, 0.83 - 1.06).",Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24161160/),,0,49051,DB08864,Rilpivirine
,27658864,concentrations,Geometric mean (90% CI) concentrations in plasma of rilpivirine at day 28 post dose were 53 ng/mL (38-67) in women and 43 ng/mL (23-63) in men for the 1200 mg dose and 28 ng/mL (19-37) in women and 17 ng/mL (9-24) in men for the 600 mg dose.,"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),[ng] / [ml],53,60788,DB08864,Rilpivirine
,27658864,concentrations,Geometric mean (90% CI) concentrations in plasma of rilpivirine at day 28 post dose were 53 ng/mL (38-67) in women and 43 ng/mL (23-63) in men for the 1200 mg dose and 28 ng/mL (19-37) in women and 17 ng/mL (9-24) in men for the 600 mg dose.,"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),[ng] / [ml],43,60789,DB08864,Rilpivirine
,27658864,concentrations,Geometric mean (90% CI) concentrations in plasma of rilpivirine at day 28 post dose were 53 ng/mL (38-67) in women and 43 ng/mL (23-63) in men for the 1200 mg dose and 28 ng/mL (19-37) in women and 17 ng/mL (9-24) in men for the 600 mg dose.,"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),[ng] / [ml],28,60790,DB08864,Rilpivirine
,27658864,concentrations,Geometric mean (90% CI) concentrations in plasma of rilpivirine at day 28 post dose were 53 ng/mL (38-67) in women and 43 ng/mL (23-63) in men for the 1200 mg dose and 28 ng/mL (19-37) in women and 17 ng/mL (9-24) in men for the 600 mg dose.,"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),[ng] / [ml],17,60791,DB08864,Rilpivirine
,27658864,tissue-to-plasma ratio,"The tissue-to-plasma ratio for rilpivirine in rectal tissue was about two-fold higher than in vaginal and cervical tissue (1·10-1·53 vs 0·61-0·72 and 0·50-0·71, respectively).","Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),,1,60792,DB08864,Rilpivirine
,27658864,tissue-to-plasma ratio,"The tissue-to-plasma ratio for rilpivirine in rectal tissue was about two-fold higher than in vaginal and cervical tissue (1·10-1·53 vs 0·61-0·72 and 0·50-0·71, respectively).","Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),,0·61-0·72,60793,DB08864,Rilpivirine
,27658864,tissue-to-plasma ratio,"The tissue-to-plasma ratio for rilpivirine in rectal tissue was about two-fold higher than in vaginal and cervical tissue (1·10-1·53 vs 0·61-0·72 and 0·50-0·71, respectively).","Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27658864/),,0·50-0·71,60794,DB08864,Rilpivirine
,30997864,tmax,"Riociguat median tmax was 1.00-1.27 h, with comparable maximum concentration (Cmax) across the five background antiretroviral groups.",Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30997864/),h,1.00-1.27,66652,DB08864,Rilpivirine
,29374296,minimal effective concentration,"Of the observed trough individual plasma concentrations, 24.4% were below the 50 ng/ml minimal effective concentration.",Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374296/),[ng] / [ml],50,68348,DB08864,Rilpivirine
,29374296,plasma apparent clearance,"The estimated fixed effect for plasma apparent clearance and distribution volume were 9 L/h and 321 L, respectively, resulting in a half-life of 25.2 h.",Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374296/),[l] / [h],9,68349,DB08864,Rilpivirine
,29374296,distribution volume,"The estimated fixed effect for plasma apparent clearance and distribution volume were 9 L/h and 321 L, respectively, resulting in a half-life of 25.2 h.",Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374296/),l,321,68350,DB08864,Rilpivirine
,29374296,half-life,"The estimated fixed effect for plasma apparent clearance and distribution volume were 9 L/h and 321 L, respectively, resulting in a half-life of 25.2 h.",Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374296/),h,25.2,68351,DB08864,Rilpivirine
,29528944,concentrations,"For all time points combined, median (interquartile range) rilpivirine concentrations were 70 ng/mL (23-121) in CVF and 92 ng/mL (49-147) in plasma.",Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29528944/),[ng] / [ml],70,71908,DB08864,Rilpivirine
,29528944,concentrations,"For all time points combined, median (interquartile range) rilpivirine concentrations were 70 ng/mL (23-121) in CVF and 92 ng/mL (49-147) in plasma.",Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29528944/),[ng] / [ml],92,71909,DB08864,Rilpivirine
,27187753,AUC0-24,"When dosed without DRV/r, the RPV geometric mean (90% confidence interval) for RPV AUC0-24, Cmax and C24 h were 2.38 μg h/mL (1.92-2.94), 0.14 μg/mL (0.12-0.18) and 0.07 μg/mL (0.03-0.10), respectively, similar to adult values.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[h·μg] / [ml],2.38,86580,DB08864,Rilpivirine
,27187753,Cmax,"When dosed without DRV/r, the RPV geometric mean (90% confidence interval) for RPV AUC0-24, Cmax and C24 h were 2.38 μg h/mL (1.92-2.94), 0.14 μg/mL (0.12-0.18) and 0.07 μg/mL (0.03-0.10), respectively, similar to adult values.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[μg] / [ml],0.14,86581,DB08864,Rilpivirine
,27187753,C24 h,"When dosed without DRV/r, the RPV geometric mean (90% confidence interval) for RPV AUC0-24, Cmax and C24 h were 2.38 μg h/mL (1.92-2.94), 0.14 μg/mL (0.12-0.18) and 0.07 μg/mL (0.03-0.10), respectively, similar to adult values.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[μg] / [ml],0.07,86582,DB08864,Rilpivirine
,27187753,AUC24,"RPV concentrations were significantly increased with concomitant DRV/r use: RPV AUC24, Cmax and C24 h were 6.74 μg h/mL (4.89-9.28), 0.39 μg/mL (0.27-0.57) and 0.23 μg/mL (0.17-0.32), respectively, well above the target ranges based on adult data.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[h·μg] / [ml],6.74,86583,DB08864,Rilpivirine
,27187753,Cmax,"RPV concentrations were significantly increased with concomitant DRV/r use: RPV AUC24, Cmax and C24 h were 6.74 μg h/mL (4.89-9.28), 0.39 μg/mL (0.27-0.57) and 0.23 μg/mL (0.17-0.32), respectively, well above the target ranges based on adult data.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[μg] / [ml],0.39,86584,DB08864,Rilpivirine
,27187753,C24 h,"RPV concentrations were significantly increased with concomitant DRV/r use: RPV AUC24, Cmax and C24 h were 6.74 μg h/mL (4.89-9.28), 0.39 μg/mL (0.27-0.57) and 0.23 μg/mL (0.17-0.32), respectively, well above the target ranges based on adult data.",Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27187753/),[μg] / [ml],0.23,86585,DB08864,Rilpivirine
,27497648,total run time,The total run time for each sample was 6min.,"Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27497648/),min,6,94165,DB08864,Rilpivirine
,28008867,trough drug concentrations,"All patients were given dolutegravir at 50 mg once daily, with median trough drug concentrations of 1,096 (664-2,356) ng/ml (interindividual coefficient of variation: 85.3%).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"1,096",96385,DB08864,Rilpivirine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"2,399",96386,DB08864,Rilpivirine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],738,96387,DB08864,Rilpivirine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],603,96388,DB08864,Rilpivirine
,28008867,drug concentrations,"Patients given dolutegravir with atazanavir had significantly higher drug concentrations compared with those given darunavir, rilpivirine or abacavir/lamivudine (2,399 [1,929-4,070] versus 738 [552-1,048], 603 [432-1,373] or 1,045 [856-1,115] ng/ml; P<0.001 for all comparisons).",Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28008867/),[ng] / [ml],"1,045",96389,DB08864,Rilpivirine
,31525446,release rates,"PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10-3-3 × 10-3h-1 and 1 × 10-3-1.5 × 10-3h-1 respectively, for a 70 kg adult.",Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),1/[h],1 × 10-,97539,DB08864,Rilpivirine
,31525446,release rates,"PBPK models simulated q4-weekly loading and maintenance doses of 360 mg and 180 mg for long-acting formulated cabotegravir between the release rates of 1 × 10-3-3 × 10-3h-1 and 1 × 10-3-1.5 × 10-3h-1 respectively, for a 70 kg adult.",Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),1/[h],1 × 10-3,97540,DB08864,Rilpivirine
,31525446,release rates,"For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10-3-2.5 × 10-3h-1 and 5 × 10-4-1 × 10-3h-1, respectively.",Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),1/[h],1.5 ×,97541,DB08864,Rilpivirine
,31525446,release rates,"For q4-weekly dosing, rilpivirine required a 1080 mg loading dose and a 540 mg maintenance dose with release rates of 1.5 × 10-3-2.5 × 10-3h-1 and 5 × 10-4-1 × 10-3h-1, respectively.",Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),,5 × 10-4,97542,DB08864,Rilpivirine
,31525446,release rates,Weekly cabotegravir required 60 mg between release rates 7 × 10-3-9 × 10-3h-1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10-3-9 × 10-3h-1.,Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),1/[h],7 × 10-3,97543,DB08864,Rilpivirine
,31525446,release rates,Weekly cabotegravir required 60 mg between release rates 7 × 10-3-9 × 10-3h-1 and rilpivirine required 270 mg and 180 mg respectively between release rates of 7 × 10-3-9 × 10-3h-1.,Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31525446/),,7 × 10-3,97544,DB08864,Rilpivirine
,29189101,Cmax,"Geometric mean and 95%CI rilpivirine Cmax, Ctrough, AUC were 183 (165-239), 114 (104-109) ng/mL, 2966 (2704-3820) ng h/mL.",Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189101/),[ng] / [ml],183,120963,DB08864,Rilpivirine
,29189101,"Ctrough, AUC","Geometric mean and 95%CI rilpivirine Cmax, Ctrough, AUC were 183 (165-239), 114 (104-109) ng/mL, 2966 (2704-3820) ng h/mL.",Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189101/),[ng] / [ml],114,120964,DB08864,Rilpivirine
,29189101,"Ctrough, AUC","Geometric mean and 95%CI rilpivirine Cmax, Ctrough, AUC were 183 (165-239), 114 (104-109) ng/mL, 2966 (2704-3820) ng h/mL.",Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189101/),[h·ng] / [ml],2966,120965,DB08864,Rilpivirine
,31225609,EC50,The population typical value of rilpivirine EC50 was estimated at 65 ng/mL.,Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31225609/),[ng] / [ml],65,121403,DB08864,Rilpivirine
,32374049,trough concentration,The optimal target for rilpivirine trough concentration was 70 ng/mL (sensitivity 75.4%; specificity 61.5%).,Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32374049/),[ng] / [ml],70,137087,DB08864,Rilpivirine
,27799217,Plasma concentrations,Plasma concentrations ranged from 12 to 255 ng/ml.,Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27799217/),[ng] / [ml],12 to 255,140149,DB08864,Rilpivirine
,27799217,clearance (CL),"The average RPV clearance (CL) was 11.7 liters/h, the average volume of distribution was 401 liters, and the mean absorption time was 4 h.",Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27799217/),[l] / [h],11.7,140150,DB08864,Rilpivirine
,27799217,volume of distribution,"The average RPV clearance (CL) was 11.7 liters/h, the average volume of distribution was 401 liters, and the mean absorption time was 4 h.",Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27799217/),l,401,140151,DB08864,Rilpivirine
,27799217,mean absorption time,"The average RPV clearance (CL) was 11.7 liters/h, the average volume of distribution was 401 liters, and the mean absorption time was 4 h.",Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27799217/),h,4,140152,DB08864,Rilpivirine
below,27799217,minimal concentrations,"None of the available demographic or genetic covariates showed any influence on RPV pharmacokinetics, but 29% of the patients were predicted to present minimal concentrations below the recently identified target cutoff value of 50 ng/ml.",Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27799217/),[ng] / [ml],50,140153,DB08864,Rilpivirine
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],135,167953,DB08864,Rilpivirine
,27999010,C trough,"The geometric mean (95% CI) of C trough of rilpivirine and dolutegravir did not change between baseline and week 4 ( P = 0.654 and P = 0.268, respectively), with corresponding overall values of 135 (102-177) and 1357 (970-1897) ng/mL.",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],1357,167954,DB08864,Rilpivirine
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],370,167955,DB08864,Rilpivirine
,27999010,C trough,"The overall geometric mean (95% CI) of GS-331007 and simeprevir C trough was 370 (268-512) and 2537 (1569-4101) ng/mL, respectively, without significant variation between weeks 2 and 4 ( P = 0.643 and P = 0.179, respectively).",Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27999010/),[ng] / [ml],2537,167956,DB08864,Rilpivirine
,27294305,area-under-the-concentration-time curve from 0 to 24 hours (,"Mean (standard deviation) rilpivirine area-under-the-concentration-time curve from 0 to 24 hours (AUC24h and C0h) were 2391 (991) ng·h/mL and 83.5 (38.7) ng/mL, respectively.","Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294305/),[h·ng] / [ml],2391,174893,DB08864,Rilpivirine
,27294305,AUC24h,"Mean (standard deviation) rilpivirine area-under-the-concentration-time curve from 0 to 24 hours (AUC24h and C0h) were 2391 (991) ng·h/mL and 83.5 (38.7) ng/mL, respectively.","Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294305/),[h·ng] / [ml],2391,174894,DB08864,Rilpivirine
,27294305,C0h,"Mean (standard deviation) rilpivirine area-under-the-concentration-time curve from 0 to 24 hours (AUC24h and C0h) were 2391 (991) ng·h/mL and 83.5 (38.7) ng/mL, respectively.","Rilpivirine as a Treatment for HIV-infected Antiretroviral-naïve Adolescents: Week 48 Safety, Efficacy, Virology and Pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294305/),[ng] / [ml],83.5,174895,DB08864,Rilpivirine
,32280940,trough concentrations (Ctrough),"In participants who received at least 1 injection, the geometric mean of overall RPV trough concentrations (Ctrough) was 62.2 ng/mL.",Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32280940/),[ng] / [ml],62.2,192004,DB08864,Rilpivirine
,32280940,CTrough,"In participants who received all six injections, the geometric mean of CTrough through the injection phase and after the last injection were 72.8 ng/mL and 100.9 ng/mL, respectively.",Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32280940/),[ng] / [ml],72.8,192005,DB08864,Rilpivirine
,32280940,CTrough,"In participants who received all six injections, the geometric mean of CTrough through the injection phase and after the last injection were 72.8 ng/mL and 100.9 ng/mL, respectively.",Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32280940/),[ng] / [ml],100.9,192006,DB08864,Rilpivirine
,32280940,Ctrough,"At week 52 (eight weeks after last injection), the geometric mean of RPV Ctrough was 75.0 ng/mL.",Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32280940/),[ng] / [ml],75.0,192007,DB08864,Rilpivirine
,31873746,total CSF concentrations,"Median total CSF concentrations in Q4W and Q8W groups, respectively, were 0.011 μg/mL and 0.013 μg/mL for cabotegravir (0.30% and 0.34% of the paired plasma concentrations) and 1.84 ng/mL and 1.67 ng/mL for rilpivirine (1.07% and 1.32% of paired plasma concentrations).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[μg] / [ml],0.011,200657,DB08864,Rilpivirine
,31873746,total CSF concentrations,"Median total CSF concentrations in Q4W and Q8W groups, respectively, were 0.011 μg/mL and 0.013 μg/mL for cabotegravir (0.30% and 0.34% of the paired plasma concentrations) and 1.84 ng/mL and 1.67 ng/mL for rilpivirine (1.07% and 1.32% of paired plasma concentrations).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[μg] / [ml],0.013,200658,DB08864,Rilpivirine
,31873746,total CSF concentrations,"Median total CSF concentrations in Q4W and Q8W groups, respectively, were 0.011 μg/mL and 0.013 μg/mL for cabotegravir (0.30% and 0.34% of the paired plasma concentrations) and 1.84 ng/mL and 1.67 ng/mL for rilpivirine (1.07% and 1.32% of paired plasma concentrations).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[ng] / [ml],1.84,200659,DB08864,Rilpivirine
,31873746,total CSF concentrations,"Median total CSF concentrations in Q4W and Q8W groups, respectively, were 0.011 μg/mL and 0.013 μg/mL for cabotegravir (0.30% and 0.34% of the paired plasma concentrations) and 1.84 ng/mL and 1.67 ng/mL for rilpivirine (1.07% and 1.32% of paired plasma concentrations).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[ng] / [ml],1.67,200660,DB08864,Rilpivirine
,31873746,total CSF concentrations,"Cabotegravir and rilpivirine total CSF concentrations exceeded their respective in vitro EC50 for WT HIV-1 (0.10 ng/mL and 0.27 ng/mL, respectively).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[ng] / [ml],0.10,200661,DB08864,Rilpivirine
,31873746,EC50,"Cabotegravir and rilpivirine total CSF concentrations exceeded their respective in vitro EC50 for WT HIV-1 (0.10 ng/mL and 0.27 ng/mL, respectively).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[ng] / [ml],0.10,200662,DB08864,Rilpivirine
,31873746,EC50,"Cabotegravir and rilpivirine total CSF concentrations exceeded their respective in vitro EC50 for WT HIV-1 (0.10 ng/mL and 0.27 ng/mL, respectively).",Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31873746/),[ng] / [ml],0.27,200663,DB08864,Rilpivirine
,29869305,solubility,The drug has low aqueous solubility (0.0166 mg/ml) and dissolution rate leading to low bioavailability (32%).,Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869305/),[mg] / [ml],0.0166,205083,DB08864,Rilpivirine
,29869305,bioavailability,The drug has low aqueous solubility (0.0166 mg/ml) and dissolution rate leading to low bioavailability (32%).,Investigation of Cyclodextrin-Based Nanosponges for Solubility and Bioavailability Enhancement of Rilpivirine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29869305/),%,32,205084,DB08864,Rilpivirine
,20160045,absolute bioavailability,"The absolute bioavailability approached 100%, indicating a complete release from the depot, in spite of rilpivirine concentrations still being high at the injection site(s) 3 months after administration in dogs.",Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160045/),%,100,224956,DB08864,Rilpivirine
,22729755,flow rate,"The reconstituted samples were chromatographed on a C(18) column using a mixture of acetonitrile and 0.1% formic acid buffer (80:20, v/v) as the mobile phase at a flow rate of 0.5 mL/min.",Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729755/),[ml] / [min],0.5,246012,DB08864,Rilpivirine
>,22729755,Extraction recoveries,Extraction recoveries of drug from plasma were >69.5%.,Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729755/),%,69.5,246013,DB08864,Rilpivirine
,22729755,run time,A run time of 2.50 min for each sample made it possible to analyze more than 300 plasma samples per day.,Liquid chromatography-tandem mass spectrometric assay for the non-nucleoside reverse transcriptase inhibitor rilpivirine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729755/),min,2.50,246014,DB08864,Rilpivirine
below,28595298,Cmin,Four of 16 (25%) subjects had Cmin below the target concentration (0.04 mg/L) in the third trimester of pregnancy.,Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28595298/),mg,0.04,249066,DB08864,Rilpivirine
,28595298,cord-to-maternal plasma concentration ratio,"The median (range, n = 5) rilpivirine cord-to-maternal plasma concentration ratio was 0.50 (range, .35-.81).",Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28595298/),,0.50,249067,DB08864,Rilpivirine
,26195515,terminal elimination plasma half-lives,"The terminal elimination plasma half-lives for tenofovir and emtricitabine over 216 h (geometric mean [90% confidence interval]) were higher than those seen over 0 to 24 h (for tenofovir, 31 h [27 to 40 h] versus 13.3 h [12.5 to 15.1 h]; for emtricitabine, 41 h [36 to 54 h] versus 6.4 h (5.9 to 7.6 h]).","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,31,250904,DB08864,Rilpivirine
,26195515,terminal elimination plasma half-lives,"The terminal elimination plasma half-lives for tenofovir and emtricitabine over 216 h (geometric mean [90% confidence interval]) were higher than those seen over 0 to 24 h (for tenofovir, 31 h [27 to 40 h] versus 13.3 h [12.5 to 15.1 h]; for emtricitabine, 41 h [36 to 54 h] versus 6.4 h (5.9 to 7.6 h]).","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,13.3,250905,DB08864,Rilpivirine
,26195515,terminal elimination plasma half-lives,"The terminal elimination plasma half-lives for tenofovir and emtricitabine over 216 h (geometric mean [90% confidence interval]) were higher than those seen over 0 to 24 h (for tenofovir, 31 h [27 to 40 h] versus 13.3 h [12.5 to 15.1 h]; for emtricitabine, 41 h [36 to 54 h] versus 6.4 h (5.9 to 7.6 h]).","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,41,250906,DB08864,Rilpivirine
,26195515,terminal elimination plasma half-lives,"The terminal elimination plasma half-lives for tenofovir and emtricitabine over 216 h (geometric mean [90% confidence interval]) were higher than those seen over 0 to 24 h (for tenofovir, 31 h [27 to 40 h] versus 13.3 h [12.5 to 15.1 h]; for emtricitabine, 41 h [36 to 54 h] versus 6.4 h (5.9 to 7.6 h]).","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,6.4,250907,DB08864,Rilpivirine
,26195515,half-lives,Model-predicted IC half-lives (0 to 168 h) were 116 h (TFV-DP) and 37 h (FTC-TP).,"Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,0 to 168,250908,DB08864,Rilpivirine
,26195515,half-lives,Model-predicted IC half-lives (0 to 168 h) were 116 h (TFV-DP) and 37 h (FTC-TP).,"Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,116,250909,DB08864,Rilpivirine
,26195515,half-lives,Model-predicted IC half-lives (0 to 168 h) were 116 h (TFV-DP) and 37 h (FTC-TP).,"Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,37,250910,DB08864,Rilpivirine
,26195515,concentration,"The plasma rilpivirine concentration at 216 h was 4.5 ng/ml (4.2 to 6.2 ng/ml), and half-lives over 0 to 216 h and 0 to 24 h were 47 h (41 to 59 h) and 35 h (28 to 46 h), respectively.","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),[ng] / [ml],4.5,250911,DB08864,Rilpivirine
,26195515,half-lives,"The plasma rilpivirine concentration at 216 h was 4.5 ng/ml (4.2 to 6.2 ng/ml), and half-lives over 0 to 216 h and 0 to 24 h were 47 h (41 to 59 h) and 35 h (28 to 46 h), respectively.","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,47,250912,DB08864,Rilpivirine
,26195515,half-lives,"The plasma rilpivirine concentration at 216 h was 4.5 ng/ml (4.2 to 6.2 ng/ml), and half-lives over 0 to 216 h and 0 to 24 h were 47 h (41 to 59 h) and 35 h (28 to 46 h), respectively.","Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26195515/),h,35,250913,DB08864,Rilpivirine
more,23614909,Recovery,Recovery of rilpivirine was more than 82.0%.,Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23614909/),%,82.0,259099,DB08864,Rilpivirine
,28994660,AUC24 h,"Mean (sd) AUC24 h, C24 h and Cmax of RPV were 2,041 (745) ng•h/ml, 69 (29) ng/ml and 143 (65) ng/ml, respectively.",Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28994660/),[h·ng] / [ml],"2,041",263178,DB08864,Rilpivirine
,28994660,C24 h,"Mean (sd) AUC24 h, C24 h and Cmax of RPV were 2,041 (745) ng•h/ml, 69 (29) ng/ml and 143 (65) ng/ml, respectively.",Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28994660/),[ng] / [ml],69,263179,DB08864,Rilpivirine
,28994660,Cmax,"Mean (sd) AUC24 h, C24 h and Cmax of RPV were 2,041 (745) ng•h/ml, 69 (29) ng/ml and 143 (65) ng/ml, respectively.",Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28994660/),[ng] / [ml],143,263180,DB08864,Rilpivirine
,28994660,Tmax,Median (IQR) Tmax was 5 (2-9) h.,Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28994660/),h,5,263181,DB08864,Rilpivirine
<,28994660,C24 h,Four adolescents had C24 h <40 ng/ml.,Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28994660/),[ng] / [ml],40,263182,DB08864,Rilpivirine
,25988676,maximum plasma concentration,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[ng] / [ml],39,266348,DB08864,Rilpivirine
,25988676,maximum plasma concentration,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[ng] / [ml],48,266349,DB08864,Rilpivirine
,25988676,maximum plasma concentration,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[ng] / [ml],140,266350,DB08864,Rilpivirine
,25988676,area under the concentration-time curve,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[h·ng] / [ml],"17,090",266351,DB08864,Rilpivirine
,25988676,area under the concentration-time curve,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[h·ng] / [ml],"25,240",266352,DB08864,Rilpivirine
,25988676,area under the concentration-time curve,"After one injection of 300, 600 or 1200 mg RPV LA, the mean (standard deviation) maximum plasma concentration was 39 (25), 48 (13) and 140 (16) ng/mL, and the mean (standard deviation) area under the concentration-time curve (28 days) was 17,090 (8907), 25,240 (8184) and 55,350 (13,550) ng h/mL, respectively.","Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[h·ng] / [ml],"55,350",266353,DB08864,Rilpivirine
,25988676,plasma concentration,The mean (standard deviation) RPV plasma concentration across the 28-day dosing interval after the last injection in the 1200/600/600 mg group was 79 (19) ng/mL.,"Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25988676/),[ng] / [ml],79,266354,DB08864,Rilpivirine
,31146534,concentrations,"Geometric mean (90% confidence interval) plasma RPV concentrations at 56 days after the first and third doses were 39 (33-45) ng/mL (female)/29 (17-40) ng/mL (male) and 59 (45-62) ng/mL (female)/40 (30-51) ng/mL (male), respectively.",A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31146534/),[ng] / [ml],39,266768,DB08864,Rilpivirine
,31146534,concentrations,"Geometric mean (90% confidence interval) plasma RPV concentrations at 56 days after the first and third doses were 39 (33-45) ng/mL (female)/29 (17-40) ng/mL (male) and 59 (45-62) ng/mL (female)/40 (30-51) ng/mL (male), respectively.",A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31146534/),[ng] / [ml],29,266769,DB08864,Rilpivirine
,31146534,concentrations,"Geometric mean (90% confidence interval) plasma RPV concentrations at 56 days after the first and third doses were 39 (33-45) ng/mL (female)/29 (17-40) ng/mL (male) and 59 (45-62) ng/mL (female)/40 (30-51) ng/mL (male), respectively.",A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31146534/),[ng] / [ml],59,266770,DB08864,Rilpivirine
,31146534,concentrations,"Geometric mean (90% confidence interval) plasma RPV concentrations at 56 days after the first and third doses were 39 (33-45) ng/mL (female)/29 (17-40) ng/mL (male) and 59 (45-62) ng/mL (female)/40 (30-51) ng/mL (male), respectively.",A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31146534/),[ng] / [ml],40,266771,DB08864,Rilpivirine
